JPRN-UMIN000017953Recruiting未知
ew assessment of therapeutic response to sorafenib for advanced hepatocellular carcinoma - New assessment of therapeutic response to sorafenib for advanced hepatocellular carcinoma
Saga-Ken Medical Centre Koseikan0 sites40 target enrollmentStarted: June 19, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •No follow-up CT images are available
Investigators
Similar Trials
Recruiting
Not Applicable
Evaluation of the safety and efficacy of sorafenib therapy after TACE for unresectable hepatocellular carcinoma (multicenter study)Hepatocellular carcinomaJPRN-UMIN000006475Kagoshima University Medical and Dental Hospital70
Active, not recruiting
Phase 1
An exploratory study of sorafenib for patients listed for transplantation due to HCCPatients >18 years with hepatocellular carcinoma, on waiting list for liver transplantationMedDRA version: 12.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentMedDRA version: 12.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableEUCTR2010-024306-36-SEVästra Götalandsregionen21
Recruiting
Phase 2
To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000007488ippon medical school100
Active, not recruiting
Phase 1
A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159
Recruiting
Not Applicable
The efficacy of sorafenib administration prior to TACE against the patients with intermediate HCC refractory to TACEHCCJPRN-UMIN000012636Keio University, School of Medicine10